These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Inhaled treprostinil for the treatment of pulmonary arterial hypertension. Poms A; Kingman M Crit Care Nurse; 2011 Dec; 31(6):e1-10. PubMed ID: 22135338 [TBL] [Abstract][Full Text] [Related]
10. The role of treprostinil in the management of pulmonary hypertension. Skoro-Sajer N; Lang I Am J Cardiovasc Drugs; 2008; 8(4):213-7. PubMed ID: 18690755 [TBL] [Abstract][Full Text] [Related]
11. Extended-release oral treprostinil in the management of pulmonary arterial hypertension: clinical evidence and experience. Coons JC; Miller T Ther Adv Respir Dis; 2018; 12():1753466618766490. PubMed ID: 29609511 [TBL] [Abstract][Full Text] [Related]
12. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Gomberg-Maitland M; Tapson VF; Benza RL; McLaughlin VV; Krichman A; Widlitz AC; Barst RJ Am J Respir Crit Care Med; 2005 Dec; 172(12):1586-9. PubMed ID: 16151039 [TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension. Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071 [TBL] [Abstract][Full Text] [Related]
14. Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. Voswinckel R; Enke B; Reichenberger F; Kohstall M; Kreckel A; Krick S; Gall H; Gessler T; Schmehl T; Ghofrani HA; Schermuly RT; Grimminger F; Rubin LJ; Seeger W; Olschewski H J Am Coll Cardiol; 2006 Oct; 48(8):1672-81. PubMed ID: 17045906 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Jing ZC; Parikh K; Pulido T; Jerjes-Sanchez C; White RJ; Allen R; Torbicki A; Xu KF; Yehle D; Laliberte K; Arneson C; Rubin LJ Circulation; 2013 Feb; 127(5):624-33. PubMed ID: 23307827 [TBL] [Abstract][Full Text] [Related]
17. Transition from intravenous or subcutaneous prostacyclin therapy to inhaled treprostinil in patients with pulmonary arterial hypertension: a retrospective case series. Enderby CY; Soukup M; Al Omari M; Zeiger T; Burger C J Clin Pharm Ther; 2014 Oct; 39(5):496-500. PubMed ID: 24806480 [TBL] [Abstract][Full Text] [Related]
18. Inhaled treprostinil sodium for the treatment of pulmonary arterial hypertension. Ferrantino M; White RJ Expert Opin Pharmacother; 2011 Nov; 12(16):2583-93. PubMed ID: 21988216 [TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension. de Jesus Perez VA; Rosenzweig E; Rubin LJ; Poch D; Bajwa A; Park M; Jain M; Bourge RC; Kudelko K; Spiekerkoetter E; Liu J; Hsi A; Zamanian RT Am J Cardiol; 2012 Nov; 110(10):1546-50. PubMed ID: 22853986 [TBL] [Abstract][Full Text] [Related]
20. Treprostinil for the treatment of pulmonary hypertension. Skoro-Sajer N; Lang I Expert Opin Pharmacother; 2008 Jun; 9(8):1415-20. PubMed ID: 18473715 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]